PURPOSE: Localized prostate cancer (LPC) patients are faced with numerous treatment options, including observation or watchful waiting. The choice of treatment largely depends on their baseline health-adjusted life expectancy (HALE). By consensus, physicians recommend treatment if the patient's HALE is ten or more years. However, the estimation of HALE is difficult. Although subjective by nature, self-rated health (SRH) is a robust predictor of mortality. We studied the usefulness of SRH in estimating HALE in patients who are considering treatment for LPC. METHODS: A total of 144 LPC patients from a large urology private practice in Norfolk, Virginia, were surveyed before they had chosen a treatment option. RESULTS: HALE determined by SRH correlated well with objective health measures and was higher than age-based life expectancy by an average of 2 years. The observed difference in life expectancy due to SRH adjustment was higher among patients with a better socioeconomic and health profile. CONCLUSIONS: SRH is an easy-to-use indicator of HALE in LPC patients. A table for HALE estimation by age and SRH is provided for men aged 70-80 years. Additional research with larger samples and prospective study designs are needed before the SRH method can be used in primary care and urology settings.
PURPOSE:Localized prostate cancer (LPC) patients are faced with numerous treatment options, including observation or watchful waiting. The choice of treatment largely depends on their baseline health-adjusted life expectancy (HALE). By consensus, physicians recommend treatment if the patient's HALE is ten or more years. However, the estimation of HALE is difficult. Although subjective by nature, self-rated health (SRH) is a robust predictor of mortality. We studied the usefulness of SRH in estimating HALE in patients who are considering treatment for LPC. METHODS: A total of 144 LPCpatients from a large urology private practice in Norfolk, Virginia, were surveyed before they had chosen a treatment option. RESULTS: HALE determined by SRH correlated well with objective health measures and was higher than age-based life expectancy by an average of 2 years. The observed difference in life expectancy due to SRH adjustment was higher among patients with a better socioeconomic and health profile. CONCLUSIONS:SRH is an easy-to-use indicator of HALE in LPCpatients. A table for HALE estimation by age and SRH is provided for men aged 70-80 years. Additional research with larger samples and prospective study designs are needed before the SRH method can be used in primary care and urology settings.
Authors: David C Miller; Stephen B Gruber; Brent K Hollenbeck; James E Montie; John T Wei Journal: J Natl Cancer Inst Date: 2006-08-16 Impact factor: 13.506
Authors: Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Michael J Thun Journal: CA Cancer J Clin Date: 2007 Jan-Feb Impact factor: 508.702
Authors: Jochen Walz; Andrea Gallina; Georg Hutterer; Paul Perrotte; Shahrokh F Shariat; Markus Graefen; Michael McCormack; Francois Bénard; Luc Valiquette; Fred Saad; Pierre I Karakiewicz Journal: Int J Radiat Oncol Biol Phys Date: 2007-04-18 Impact factor: 7.038
Authors: Nadia A Nabulsi; Ali Alobaidi; Brian Talon; Alemseged A Asfaw; Jifang Zhou; Lisa K Sharp; Karen Sweiss; Pritesh R Patel; Naomi Y Ko; Brian C-H Chiu; Gregory S Calip Journal: Cancer Causes Control Date: 2020-04-30 Impact factor: 2.506
Authors: David A Alter; Dennis T Ko; Jack V Tu; Therese A Stukel; Douglas S Lee; Andreas Laupacis; Alice Chong; Peter C Austin Journal: J Gen Intern Med Date: 2012-05-02 Impact factor: 5.128